Heartflow (NASDAQ:HTFL) Given New $39.00 Price Target at Wells Fargo & Company

Heartflow (NASDAQ:HTFL) had its price objective upped by Wells Fargo & Company from $37.00 to $39.00 in a research report released on Friday,Benzinga reports. They currently have an overweight rating on the stock.

A number of other equities analysts have also issued reports on the stock. Robert W. Baird set a $45.00 target price on shares of Heartflow in a research report on Friday. Morgan Stanley raised their price target on shares of Heartflow from $35.00 to $40.00 and gave the stock an “equal weight” rating in a research report on Friday. Freedom Capital upgraded shares of Heartflow to a “strong-buy” rating in a report on Tuesday, June 30th. Piper Sandler reaffirmed an “overweight” rating and set a $45.00 price objective (up from $38.00) on shares of Heartflow in a research report on Friday. Finally, Stifel Nicolaus increased their target price on shares of Heartflow from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.43.

Heartflow Stock Up 35.7%

Shares of NASDAQ:HTFL opened at $42.08 on Friday. The company has a market cap of $3.63 billion and a price-to-earnings ratio of -22.99. The business has a 50 day moving average price of $29.08 and a 200 day moving average price of $27.80. Heartflow has a twelve month low of $20.13 and a twelve month high of $43.00.

Heartflow (NASDAQ:HTFL) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.15. Heartflow had a negative return on equity of 23.50% and a negative net margin of 55.82%.The company had revenue of $64.08 million for the quarter. The firm’s quarterly revenue was up 47.7% on a year-over-year basis. Analysts anticipate that Heartflow will post -0.82 EPS for the current year.

Insider Buying and Selling at Heartflow

In other news, insider Campbell Rogers sold 9,219 shares of the stock in a transaction on Monday, May 18th. The shares were sold at an average price of $28.34, for a total value of $261,266.46. Following the completion of the transaction, the insider owned 78,731 shares in the company, valued at approximately $2,231,236.54. This represents a 10.48% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John C.M. Farquhar sold 38,900 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $35.00, for a total transaction of $1,361,500.00. Following the transaction, the chief executive officer directly owned 457,935 shares of the company’s stock, valued at $16,027,725. The trade was a 7.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 115,805 shares of company stock valued at $3,530,609. 7.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Heartflow

Hedge funds and other institutional investors have recently modified their holdings of the stock. XXEC Inc. acquired a new stake in shares of Heartflow in the 2nd quarter valued at $2,524,764,000. BlackRock Inc. bought a new position in Heartflow during the 2nd quarter valued at about $152,502,000. Wellington Management Group LLP acquired a new position in Heartflow in the third quarter valued at about $164,263,000. Jupiter Topco LLC acquired a new position in Heartflow in the second quarter valued at about $70,983,000. Finally, Schusterman Interests LLC bought a new stake in Heartflow during the third quarter worth about $65,274,000.

Heartflow News Summary

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Heartflow reported second-quarter revenue of $64.1 million, up 47.7% year over year, while its adjusted loss of $0.07 per share beat the consensus estimate of a $0.22 loss. The results also showed improving profitability, with adjusted EBITDA losses narrowing to $6.7 million from $10.1 million a year earlier. Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $246 million-$250 million from $228 million-$232 million, above the roughly $230 million analyst consensus, and projected non-GAAP gross margin of about 82%. HeartFlow Shares Soar Following Strong Q2 Results and Upgraded Guidance
• Positive Sentiment: Growth was supported by stronger U.S. FFRCT volume and increasing adoption of the Plaque product, suggesting Heartflow’s AI-based coronary disease platform is broadening beyond its core business.
• Positive Sentiment: Analysts raised their targets following the report: JPMorgan increased its target to $45 and Stifel raised its target to $45, with both firms maintaining bullish ratings. Wells Fargo also raised its target to $39 and retained an “overweight” rating. Analyst Price Target Updates
• Neutral Sentiment: The strong move pushed the stock near its 52-week high, potentially increasing volatility and making valuation a greater consideration for investors despite improving operating trends.
• Negative Sentiment: Insiders have reported repeated open-market sales, including a 22,562-share sale by CEO John C.M. Farquhar. The transaction was made under a pre-arranged Rule 10b5-1 plan, which reduces its significance as a discretionary bearish signal, but continued insider selling may still weigh on sentiment. Heartflow CEO Sells Shares

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.